idea-012 · vet · queued-research
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
This candidate has no ## Wrap section yet, so there is no plain-language summary, no quoted load-bearing condition per lens, and no named cheapest next test. Run /wrap idea-012 to write one.
| Intended use | For subcutaneous placement by a licensed veterinarian or veterinary technician; in dogs and cats with diagnosed diabetes mellitus, to provide continuous interstitial; glucose readings for insulin-dose titration and hypoglycemia detection in the clinic and at; the owner's home, as an alternative to serial blood-glucose-curve sampling by repeated; venipuncture or lancet stick. |
|---|---|
| Mechanism | Subcutaneously-inserted enzymatic (glucose oxidase, amperometric) filament-type; continuous glucose sensor, re-engineered from the decades-old glucose-oxidase amperometric; sensing chemistry underlying first-generation human CGM products, in an adhesive/wrap form; factor designed for haired skin (clipped-site or fur-parting adhesive rather than a; human-skin patch), paired with a handheld or app-based reader, and a species-specific; calibration algorithm accounting for feline/canine interstitial glucose kinetics and; hematocrit ranges that differ from the human ranges the underlying sensing chemistry was; originally calibrated against |
| Device class | # Premarket classification genuinely has no referent for the launch; n/a — veterinary-only device. FDA does not premarket-review animal-only devices.; 21 CFR 807.65(b) exempts "a manufacturer of devices to be used solely for veterinary; purposes" from device establishment registration, and 807.20(a) / 807.81(a) / 814.1(a); all attach their duties to devices "intended for human use."; Class II — 21 CFR 862.1355 ("Integrated continuous glucose monitoring system," NOT; "Glucose test system" — that name belongs to 862.1345, a different Class II regulation; see Verifier correction on the matching Claims-section line) — the HUMAN-USE ANALOG ONLY.; The Class II / CGM-coverage substance is verified as a counterfactual for comparison (the; regulation covering products such as the human FreeStyle Libre and Dexcom lines, confirmed; via classification --device-name "continuous glucose monitoring system" →; product_code=QLG, regulation 862.1355); it is not this product's class and scoring Factor 1; from it would score a different, human-labeled product. |
| Predicate or analog | No veterinary-cleared or veterinary-specific predicate exists or can; exist, because FDA does not premarket-review veterinary-only devices. The closest analogs; are human continuous glucose monitors used off-label in veterinary practice: Abbott; FreeStyle Libre (multiple generations, including FreeStyle Libre 3) and, more distantly,; Dexcom G6/G7. Published veterinary literature documents off-label FreeStyle Libre use and; accuracy testing in diabetic cats and dogs (see claims). These are cited as mechanism and; market analogs only, never as a regulatory predicate — there is no premarket pathway for; either the analog or this candidate to hold one against. |
| Launch jurisdiction | US |
| Target | vet |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 4 | Connector check of full 21 CFR 807.65(b) text plus 807.20(a)/814.1(a) applicability against this exact intended-use statement (CFR-text lookup), confirming no premarket pathway attaches to a veterinary-only indication |
| Reimbursement pathway | 1 | Review of major pet-insurance policy documents (e.g. Trupanion, Nationwide, ASPCA) for any CGM-device coverage precedent — a licensed/human-attached report, since no connector in this repo reaches pet-insurance data |
| TAM | 1 | (a) diagnosed-and-treated diabetic dog/cat population count — a veterinary epidemiology study or a Banfield/BluePearl "State of Pet Health"-style report; (b) per-unit cash price — human CGM retail/cash-pay pricing data (Abbott/Dexcom); (c)…the rest of this gap analysisaddressable share — a veterinary CGM adoption survey or market report (licensed, human-attached) |
| FTO / IP | 2 | A formal patent search (USPTO/Google Patents/PatFT) for active glucose-oxidase CGM sensor, membrane-chemistry, and manufacturing-process patents held by Abbott, Dexcom, and Medtronic — named patent numbers and expiration dates |
| Moat / defensibility | 1 | A competitive scan for veterinary-specific CGM patent filings, trade dress, or trademark activity by incumbents (Abbott, Dexcom, Zoetis, Heska) that would create switching costs or blocking IP beyond the base chemistry |
| Mechanism & clinical risk | 3 | Primary-source read of the cited studies — capture full PMCIDs for the 2025 FreeStyle Libre 3 feline accuracy study and the ScienceDirect canine/feline CGM study — and their reported MARD/accuracy figures against a venous-glucose reference |
| Capital intensity & time-to-revenue | 3 | A build cost-and-timeline model for a veterinary-only sensor/reader launch (contract-manufacturer quotes, comparable veterinary device launch timelines) — a report a human would need to attach, since no connector in this repo estimates…the rest of this gap analysisdevelopment cost or timeline |
| Competitive intensity | — | A market scan for veterinary CGM competitors or off-label distribution programs already operating, plus recent funding/launch/recall activity in veterinary diabetes monitoring |
| Strategic fit & portfolio balance | — | Not source-checkable by a connector — this is a human/strategic judgment call (hero bet vs. cash-generative spoke) to be made if/when this candidate advances, not a claim to verify |
To finish this packet:
## Wrap section with a **Cheapest next test:** lineDomain dossier: veterinary-diabetes-glucose-monitoring
Source file: knowledge-base/candidates/idea-012.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.